AbsTRACT INTROduCTION The risk of clinical complications in antiphospholipid syndrome (APS) increases when a patient is positive for all 3 types of antiphospholipid (aPL) antibodies. However, there is a considerable disagreement between various platforms for aCL and anti-β 2 -glycoprotein I (anti-β 2 GPI) measurement, which leads to discrepancies between these platforms in assessing aPL antibody positivity.
antiphospholipid antibody (aPL) status of a patient has a major impact on the consistency in diagnosis across different institutions.
The consensus statement (published in 2006) advises investigators to classify patients with APS into groups based on the number of laboratory criteria present: I) more than 1 laboratory criterion present (any combination); IIa) lupus anticoagulant (LAC) present alone; IIb) aCL antibody present alone; and IIc) anti-β 2 GPI antibody present alone.
1 Since then, a large number of publications have demonstrated that aPL antibody INTROduCTION The international consensus statement on the classification criteria for definite antiphospholipid syndrome (APS) specifies anticardiolipin (aCL) and anti-β 2 -glycoprotein I (anti-β 2 GPI) antibodies of the immunoglobulin (Ig) G or IgM isotype in a medium or high titer as one of the laboratory criteria.
1 However, the agreement between various methods for aCL and anti-β 2 GPI antibody measurement is known to be suboptimal owing to discrepancies in the cutoff value, calibration, and technology.
2-5 Consequently, the method that is used to assess the were then stored at -80°C until further analysis. For the detection of LAC, blood was drawn in sodium citrate tubes (3.2% [0.109 mol/l]; 1 part sodium citrate to 9 parts venous blood). Platelet--poor plasma was prepared by double centrifugation within 2 hours (first: 10 min/3500 rpm and second: 10 min/14000 rpm) and stored at -80°C for further analysis. measurement of autoantibodies All samples were tested for aCL and anti-β 2 GPI antibodies of IgG and IgM isotypes with QUANTA Flash® CIA and QUANTA Lite® ELISA (Inova Diagnostics Inc., San Diego, California, United States) according to the manufacturer's instructions. The presence of LAC was also tested.
QUANTA Flash® aCL and aβ 2 GPI are semiquantitative immunoassays that are run on the fully automated BIO-FLASH® instrument (Biokit S.A., Barcelona, Spain). Results are expressed in (arbitrary) chemiluminescent units.
QUANTA Lite® aCL and anti-β 2 GPI are standard ELISAs for the semiquantitative determination of aCL and anti-β 2 GPI antibodies. The QUANTA Lite® aCL assays report results in GPL and MPL units, and the QUANTA Lite® β 2 GPI assays-in (arbitrary) standard IgG and IgM units.
For the purposes of this study and in accordance with the international guidelines on aCL and anti-β 2 GPI antibody testing, only the values above the 99th percentile of the results obtained from 120 sex-and age-matched reference subjects were defined as positive.
LAC was determined in a 3-step procedure according to the guidelines of the International Society on Thrombosis and Haemostasis. 15 Diluted Russell's viper venom time (LA1-screen; Siemens, Erlangen, Germany) and a sensitive activated partial thromboplastin time (Diagnostica Stago, Gennevilliers, France) were used as screening tests, and LA2-confirm (Siemens) and Staclot LA (Diagnostica Stago)-as confirmatory tests. A reference value was established using the 99th percentile value obtained in the healthy population. A triple aPL antibody positive profile was defined as positivity for LAC and for aCL and anti-β 2 GPI antibodies of the same isotype by the same method.
single versus triple antibody positivity Single aPL antibody positivity was defined as positivity for one of the following: LAC, aCL antibody, or anti-β 2 GPI antibody. Triple antibody positivity was defined as a positive result in 3 different aPL antibody assays, namely, LAC and aCL and anti--β 2 GPI antibody of the same isotype.
7,8
statistical analysis A statistical analysis was performed using the Analyse-It Software (Version 4.00.1, Leeds, United Kingdom). The Spearman's correlation and Cohen's kappa coefficient tests were performed to assess the quantitative correlation between unit values and qualitative agreement between portions, and P values of less than profiling is useful not only as a diagnostic tool but also for assessing thrombotic risk. 5, 6 The risk for the first thrombosis in asymptomatic aPL antibody carriers was strongly associated with a triple positive antibody profile in several independent studies, where triple positivity was defined as a positive result in 3 different aPL antibody assays. [7] [8] [9] Moreover, the cumulative incidence of thromboembolic events during a 10-year follow-up of patients with symptomatic APS was 44.2% in those with 3 positive aPL antibody results. 10 Pregnancy failure during conventional therapies was also independently associated with triple aPL antibody positivity. 11 It has been demonstrated that when initially positive aPL testing was repeated after 12 weeks according to the recommendations of the classification criteria, 98% of the subjects with triple antibody positivity had their aPL antibody status confirmed, in contrast with only 40% of single-positive subjects.
12 These results suggest that triple positivity allows to diagnose APS with high reliability.
Given the importance of the triple positive aPL antibody status, our goal was to assess whether 2 different measurement methods, an enzymelinked immunosorbent assay (ELISA) and a novel microparticle chemiluminescent immunoassay (CIA), identify the same subjects with APS and comorbid autoimmune diseases as triple positive.
PATIENTs ANd mEThOds Patients
This was a retrospective cross-sectional study including 220 patients. Samples were collected at the Immunological Outpatient Clinic, Department of Internal Medicine, Jagiellonian University Medical College (Kraków, Poland) from patients referred to the clinic with a suspicion of systemic lupus erythematosus (SLE) or APS (or both). Of 220 patients, 74 had the diagnosis of primary APS; 47, of secondary APS; and 99, of SLE without APS. In the group of patients with secondary APS, 46 patients were diagnosed with SLE and 1 with mixed connective tissue disease. Data on the history of venous thrombosis, arterial thrombosis, and obstetric complications were available for all subjects. Thrombotic complications were confirmed in 111 patients (81 episodes of venous thrombosis and 43 episodes of arterial thrombosis), and pregnancy morbidity-in 30 of 97 women ever pregnant. A diagnosis of APS was made on the basis of the updated APS criteria.
1 SLE was diagnosed according to the updated criteria of the American College of Rheumatology, whenever at least 4 criteria were fulfilled. 13, 14 The study was approved by a local ethics committee, and informed consent was obtained from all patients according to the Declaration of Helsinki.
sample preparation Blood samples for the measurement of aCL and anti-β 2 GPI antibodies were collected in serum separation tubes and spun for 10 minutes at 3500 rpm at room temperature within 2 hours from sampling. 
Clinical performance of triple antibody positive status
Despite significant differences between the clinical performance of individual QUANTA Lite® and QUANTA Flash® assays, when patients were classified as having single, double, and triple positivity, the number of triple-positive patients as detected by the 2 platforms was very similar (80 by QUANTA Lite® and 86 by QUANTA Flash®), while there was a significant discrepancy in the number of single-positive patients (40 by QUANTA Lite® and 21 by QUANTA Flash®). Altogether, 74 of 80 (92.5%) and 79 of 86 (91.9%) triple-positive patients had APS based on a historical 0.05 were considered significant. A receiver operating characteristic (ROC) curve analysis was used to assess the diagnostic performance of the different immunoassays, and the odds ratio (OR) was calculated to assess the association between aPL antibodies and thrombotic risk.
REsuLTs Clinical performance of individual antibody
assays Overall diagnostic efficacy To assess the diagnostic efficacy of the various immunoassays, the ROC curve analysis was performed for APSrelated clinical symptoms (any thromboembolic and obstetric complications). The results are presented in TAbLE 1. The area under the ROC curve values ranged from 0.78 to 0.82. A pair--wise comparison of QUANTA Flash® and QUANTA Lite® ROC curves did not reveal any significant differences for either aCL or anti-β 2 GPI antibodies.
sensitivity and specificity Sensitivity and specificity of aCL IgM antibodies for detecting APS--related clinical symptoms (thrombosis and obstetric complications) were significantly different between the 2 platforms, with the QUANTA Lite® assay being more sensitive (54.5% vs 31.4%) but less specific (89.9% vs 92.9%) than the QUAN-TA Flash® aCL IgM assay (TAbLE 2) . On the other hand, the QUANTA Lite® anti-β 2 GPI IgG test was Abbreviations: see TAbLE 1 regardless of the method. The OR for APS-related symptoms was 24.9 based on QUANTA Lite® results and 24.7 based on QUANTA Flash® results. This value is similar to the OR of 33.3 reported by Pengo et al 6 in a large Italian cohort. Moreover, despite the differences between individual assays, we observed a total agreement of 95.5% for triple positivity between QUANTA Lite® and QUANTA Flash® platforms, demonstrating that the 2 methods identified the same patients as triple-positive. This finding has important implications for the future use of aPL antibody results because it suggests that the agreement between various platforms is better when assessing aPL antibody profiles than when assessing individual antibodies. In conclusion, our results not only confirm that triple aPL positivity has a strong association with APS, but also demonstrate that the identification of patients with triple antibody positivity is platform independent.
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diagnosis. When APS-related clinical symptoms were considered instead of the diagnosis of APS (to avoid a diagnostic bias), an odds ratio was 24.9 for QUANTA Lite® and 24.7 for QUANTA Flash® in triple-positive patients. dIsCussION In this cross-sectional study, we have shown that 2 different platforms, an automated microparticle CIA and a traditional ELISA, identified the same patients as having triple aPL antibody positivity.
Over the last decade, a significant progress has been made in the diagnosis and management of APS. Beside the identification of new and promising aPL antibody specificities (antiphosphatidylserine/prothrombin and anti-β 2 GPI Domain 1 antibodies), 16 several new concepts have been introduced, such as risk stratification, antibody profiling, and establishment of aPL antibody scores.
6,17-20 New technologies and platforms have also emerged with favorable analytical and clinical characteristics. 17, 21, 22 One of the most important recent findings is the identification of triple antibody positivity as a strong diagnostic and risk stratification tool. [6] [7] [8] [9] [10] [11] [12] 21, 23, 24 Triple positivity has the potential of becoming an excellent laboratory tool for diagnosing APS and predicting thrombosis, but its usefulness may be hindered by the variable performance of different aPL antibody assays. Discrepancies between methods may lead to identifying different patients as triple positive depending on a platform or assay.
At the level of individual aPL antibodies, specifically for aCL IgM and anti-β 2 GPI IgG, significant differences were identified between the QUANTA Lite® and QUANTA Flash® assays in clinical sensitivity and specificity, together with a high level of disagreement in the classification of patients as antibody positive or negative. However, we have shown that a similar number of triple-positive patients were identified by the 2 methods: 80 with QUANTA Lite® and 86 with QUANTA Flash®. In addition, we have confirmed a strong association between triple antibody positivity and APS, 
